Femasys appoints Kelley Nicholas as CCO; grants 100,000-share inducement option

FEMASYS INC

Appointed Kelley Nicholas as Chief Commercial Officer effective June 17, 2025; she will lead U.S. commercialization and global partnerships.
Nicholas brings over 25 years experience from NeuroPace, Hologic, Medtronic, Baxter, Intuitive Surgical.
As inducement, Femasys granted option to purchase 100,000 shares vesting over 4 years (25% after 1 year, then 25% annually).
Focus on expanding U.S. infertility market for FemaSeed and building international partnerships across full portfolio.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.